Literature DB >> 9708213

Cytokeratin positive T cell malignant lymphoma.

W G McCluggage1, M el-Agnaff, M D O'Hara.   

Abstract

A high grade T cell malignant lymphoma is described in which weak staining of tumour cells for leucocyte common antigen and T cell markers coexisted with strong positive cytoplasmic staining with the anticytokeratin marker CAM 5.2. This is the first report of non-CD30 positive T cell lymphoma showing cytokeratin positivity. On ultrastructural examination there was no evidence of epithelial differentiation or of accumulation of cytokeratin-type intermediate filaments. The case adds to the range of malignant lymphomas which can, on rare occasions, show cytokeratin positivity. Pathologists should be aware of this potential diagnostic pitfall if inappropriate investigations and therapeutic regimens are to be avoided.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708213      PMCID: PMC500707          DOI: 10.1136/jcp.51.5.404

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Common acute lymphoblastic leukaemia-lymphoma expressing cytokeratin: a case report.

Authors:  F Menestrina; M Lestani; A Scarpa; G Viale; F Bonetti; G Pizzolo; M Chilosi
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

2.  Cytokeratin in anaplastic large cell lymphoma.

Authors:  H F Frierson; F J Bellafiore; M J Gaffey; W S McCary; D J Innes; M E Williams
Journal:  Mod Pathol       Date:  1994-04       Impact factor: 7.842

3.  Immunoreactive cytokeratins in plasmacytomas.

Authors:  A C Wotherspoon; A J Norton; P G Isaacson
Journal:  Histopathology       Date:  1989-02       Impact factor: 5.087

4.  Cytokeratin-positive large-cell lymphomas of B-cell lineage. A study of five phenotypically unusual cases verified by polymerase chain reaction.

Authors:  J Lasota; E Hyjek; C H Koo; J Blonski; M Miettinen
Journal:  Am J Surg Pathol       Date:  1996-03       Impact factor: 6.394

5.  Gastric large cell lymphoma expressing cytokeratin but no leukocyte common antigen. A diagnostic dilemma.

Authors:  A de Mascarel; J P Merlio; J M Coindre; J F Goussot; A Broustet
Journal:  Am J Clin Pathol       Date:  1989-04       Impact factor: 2.493

6.  Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas.

Authors:  C Gustmann; M Altmannsberger; M Osborn; H Griesser; A C Feller
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

7.  CD30 (Ki-1)-positive, anaplastic large cell lymphoma mimicking gastrointestinal carcinoma.

Authors:  C W Ross; C A Hanson; B Schnitzer
Journal:  Cancer       Date:  1992-11-15       Impact factor: 6.860

8.  Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential.

Authors:  M J Hendrix; E A Seftor; Y W Chu; R E Seftor; R B Nagle; K M McDaniel; S P Leong; K H Yohem; A M Leibovitz; F L Meyskens
Journal:  J Natl Cancer Inst       Date:  1992-02-05       Impact factor: 13.506

9.  Frequent expression of haemopoietic and non-haemopoietic antigens by neoplastic plasma cells: an immunohistochemical study using formalin-fixed, paraffin-embedded tissue.

Authors:  U R Petruch; H P Horny; E Kaiserling
Journal:  Histopathology       Date:  1992-01       Impact factor: 5.087

10.  IgD myeloma/immunoblastic lymphoma cells expressing cytokeratin.

Authors:  H F Sewell; W D Thompson; D J King
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

  10 in total
  2 in total

1.  Cytokeratin positivity in anaplastic large cell lymphoma: a potential diagnostic pitfall in misdiagnosis of metastatic carcinoma.

Authors:  Qingfu Zhang; Jian Ming; Siyang Zhang; Bo Li; Xue Han; Xueshan Qiu
Journal:  Int J Clin Exp Pathol       Date:  2013-03-15

2.  Metasin-an intra-operative RT-qPCR assay to detect metastatic breast cancer in sentinel lymph nodes.

Authors:  Salma Al-Ramadhani; Priya Sai-Giridhar; Dilushana George; Preethi Gopinath; Evdokia Arkoumani; Samar Jader; Maryse Sundaresan; Roberto Salgado; Dennis Larsimont; Stephen A Bustin; Vasi Sundaresan
Journal:  Int J Mol Sci       Date:  2013-06-24       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.